High prevalence of peripheral arterial disease in patients with previous cerebrovascular or coronary event

Figures & data

Table I. Demographics of patients according to level of ankle–brachial index (ABI).

	ABI> 0.90	0.90≤ABI>0.40	ABI≤0.40
Number of patients	625	322	18
Height (cm)	171 (±8.48)	170 (±8.0)	169 (±7.9)
Weight (kg)	80 (±14.4)	78 (±14.7)	73 (±12.8)
BMI	27.3 (±4.1)	27.0 (±4.2)	25.5 (±3.6)
ABI	1.05 (±0.10)	0.73 (±0.13)	0.34 (±0.05)
Systolic blood pressure (mmHg)	138 (±16.5)	141 (±20.6)	151 (±24.5)
Diastolic blood pressure (mmHg)	79 (±10.4)	78 (±12.5)	76 (±10.3)
Pulse pressure (mmHg)	59 (±14.6)	64 (±17.3)	75 (±24.6)
Heart rate (min^−1)	70 (±10.1)	71 (±11.4)	72 (±9.5)
Total cholesterol (mmol/l)	4.52 (±0.98)	4.49 (±1.02)	5.08 (±0.77)
HDL-cholesterol (mmol/l)	1.48 (±0.41)	1.49 (±0.50)	1.46 (±0.48)
LDL-cholesterol (mmol/l)	2.40 (±0.79)	2.37 (±0.88)	2.95 (±0.86)
Triglyceride (mmol/l)	1.43 (±0.88)	1.49 (±0.80)	1.80 (±0.98)

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein Data are given as mean values with standard deviation in brackets.

Figure 1. Distribution of medication in patients with previous coronary or cerebrovascular events. The bars show the percentage of patients with either coronary (red, n=516) or cerebrovascular (blue, n=439) inclusion events receiving beta-blockers (BB), diuretics (Diur), angiotensin converting enzyme inhibitors/angiotensin II antagonists (ACEI/AIIA), calcium-channel blockers (CCB), acetylsalicylic acid (ASA), dipyridamol (Dipyr), statin, or clopidogrel (Clopid).